Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORT With or Without High-Dose Methotrexate for Newly Diagnosed Primary CNS Lymphoma
ChiCTR2200062302Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
methotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2200062302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062302.